EHA 2024

Markus Rückert, PhD
Medical Director

Markus is a seasoned biopharmaceutical expert specializing in oncology and rare diseases, boasting over 20 years of extensive experience in leadership positions across renowned organizations such as Ipsen Pharma, CSL Vifor, and MorphoSys, among others. Proficient in clinical development and Medical Affairs, as well as experimental and real-world evidence generation, Markus has successfully navigated various stages of drug development—from discovery to market launch—with a keen focus on advancing oncological and rare disease therapies for tangible patient benefits. Having achieved significant milestones in oncology and rare disease therapeutics, Markus now channels his diverse expertise towards broader pursuits in epidemiology, health service research, and the real-world impact of oncological treatments. Holding a PhD in biochemistry and pharmacology, Markus has contributed academically to esteemed institutions such as the University of Würzburg, Germany, and the Karolinska Institutet, Stockholm, Sweden.

Guillaume Azarias, PhD
Senior Data Scientist

Guillaume Azarias, PhD, is a Senior Data Scientist at TriNetX Oncology. With 15 years of academic research experience in Neuroscience and Oncology from renowned institutions such as Karolinska Institutet in Stockholm, Sweden, and the University of Zürich in Switzerland, Guillaume specializes in translating complex medical data into actionable insights and identifying unmet needs in Hemato-Oncology treatments. 

At TriNetX Oncology, Guillaume focuses on developing collaborative data science tools to accelerate the generation of Real World Evidence (RWE). His expertise has contributed to creating regulatory-grade Real World Data (RWD) across multiple European countries. By breaking down data silos, harmonizing data models, and integrating federated learning techniques, he enhances RWD quality. These initiatives are essential for advancing research networks and generating virtual twins to explore curative approaches for hematological cancers such as Multiple Myeloma.

Kai Strobel
Senior Data Analyst and Lead Epidemiologist

Kai Strobel is Senior Data Analyst and Lead Epidemiologist at TriNetX Oncology in Freiburg, Germany. Kai has years of experience collecting regulatory-grade RWD in Germany and other European countries (UK, France, and Spain), as well as the generation of RWE for research and successful HTA applications within the field of oncology. His experience broadly covers Health Economics and Outcomes Research (HEOR) topics with a focus on haematology-oncology, having published on multiple myeloma epidemiological trends in Germany and chronic lymphocytic leukemia treatment in the clinical reality in Germany and Spain.

Kai aims to contribute to a future where data-driven decisions significantly enhance the efficacy and efficiency of oncological treatments for meeting unmet needs and improving patient outcomes.

Zuzana Dostalova
Data Scientist

Zuzana is a Data Scientist at TriNetX Oncology, a wholly owned subsidiary of TriNetX, specializing in real-world data oncology research. She focuses on innovation and data quality to transform raw data into meaningful insights that support cancer research and patient care.

By leveraging data science, Zuzana addresses challenges in oncology and ensures high standards of data accuracy and reliability. She collaborates closely with researchers, clinicians, and other data analysts to produce scientifically robust and clinically applicable findings.

Passionate about continuous learning and professional growth, Zuzana’s work aims to enhance the understanding of cancer and improve patient outcomes through informed and personalized treatments. Her efforts bridge the gap between data science and clinical practice, driving cancer research and patient care advancements.